Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-13 pm EST			5-day change	1st Jan Change
100.98 ^USD	+1.74%		+1.26%	+1.51%

01:30am	Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM
Jan. 13	GSK Acquiring US-Based IDRx for up to $1.15 Billion	MT

Bernstein Trims Price Target on Merck to $110 From $115

December 02, 2024 at 06:25 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Merck & Co., Inc.

Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM	07:30pm
GSK Acquiring US-Based IDRx for up to $1.15 Billion	Jan. 13	MT
Philips CEO sees subdued China sales this year	Jan. 13	RE
Leerink Partners Adjusts Price Target on Merck $119 From $136, Keeps Outperform Rating	Jan. 13	MT
Atropos Health, Inc. Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments	Jan. 10	CI
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma	Jan. 09	MT
Global markets live: Cintas, Amazon, Tesla, Shell, Lufthansa...	Jan. 08
Wall Street's rate cut dreams wane	Jan. 08
UBS Cuts Price Target on Merck to $120 From $125, Maintains Buy Rating	Jan. 08	MT
Merck: HPV vaccine for men approved in China	Jan. 08	CF
Merck Says Gardasil HPV Vaccine Approved for Males in China	Jan. 08	MT
Merck?s GARDASIL® Receives Expanded Approval for Males in China	Jan. 08	CI
Analyst recommendations: Adobe, Merck, Take-Two, Palantir, Experian...	Jan. 08
Truist Securities Downgrades Merck to Hold From Buy, Adjusts Price Target to $110 From $130	Jan. 08	MT
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck	Jan. 07	MT
Merck Agrees to Acquire WuXi Biologics' Ireland Facility for $500 Million	Jan. 07	MT
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million	Jan. 07	DJ
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Jan. 03	MT
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Dec. 31	MT
Merck to Discontinue Zinplava for Clostridioides Difficile Infection	Dec. 24	MT
Merck: LM-299 antibody agreement finalized	Dec. 20	CF
Merck Closes Global License Deal for LM-299 with LaNova Medicines	Dec. 20	MT
Merck Closes Exclusive Global License Agreement for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody	Dec. 20	CI
BMO Capital Downgrades Merck & Co. to Market Perform From Outperform, Adjusts Price Target to $105 From $136	Dec. 20	MT
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla...	Dec. 20

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

71,000

Sector

Pharmaceuticals

Calendar

07:30pm - JP Morgan Healthcare Conference

More about the company